Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

LNTHBullishIndustry Newsnews

High materiality8/10

CMS Grants TPT and HCPCS for PYLARIFY TruVu, Expanding LNTH PSMA PET Access

Sep 30, 2026, 8:37 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

TPT and HCPCS code issuance reduce reimbursement friction and enable hospital outpatient reimbursement, likely boosting near-term demand and utilization of PYLARIFY TruVu; phased rollout mitigates supply risk but still provides a meaningful upgrade to LNTH's PSMA PET growth trajectory.

AI summary

What happened, with direct paths to the underlying reporting

CMS has granted Transitional Pass-Through (TPT) status and a permanent HCPCS code for PYLARIFY TruVu, effective October 1, 2026, enabling separate reimbursement in hospital outpatient settings. This milestone supports broader Medicare access and could lift demand for LNTH's PSMA PET imaging franchise as TruVu improves manufacturing efficiency and geographic reach. A phased rollout should mitigate near-term supply risks while expanding patient access.

CMS grants Transitional Pass-Through (TPT) status for PYLARIFY TruVu, effective Oct 1, 2026.
TruVu also earns a permanent HCPCS code to facilitate provider reimbursement.
Phased geographic rollout aims to expand PSMA-PET access and manufacturing efficiency.
Lantheus expects TruVu to drive broader adoption with improved supply and payer access.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.